Our Oncology Products
Welcome to the Pierre Fabre international website in English.
For regulatory information specific to your pharmaceutical market, please visit the website in question.
This international website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
|
BRAFTOVI 
|
BRAFTOVI (encorafenib) is a BRAF inhibitor, indicated in the European Union : - in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation - in association with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, who have received prior systemic therapy - in combination with cetuximab and FOLFOX for the first line treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation -in combination with MEKTOVI (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAFV600E mutation |
|
MEKTOVI 
|
MEKTOVI (binimetinib) is a MEK inhibitor indicated in the European Union : - in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. - in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation. |
|
NAVELBINE IV 
|
NAVELBINE (vinorelbine) is an antineoplastic agent indicated in adult patients for treatment of : - Advanced non-small cell lung cancer as monotherapy or in combination with other chemotherapy - As adjuvant treatment of non-small-cell lung cancer in combination with platinum-based chemotherapy - Advanced breast cancer as monotherapy or in combination with other agents.
|
|
NAVELBINE Oral 
|
NAVELBINE (vinorelbine) is an antineoplastic agent indicated in adult patients for treatment of : - Advanced non-small cell lung cancer as monotherapy or in combination with other chemotherapy - As adjuvant treatment of non-small-cell lung cancer in combination with platinum-based chemotherapy - Advanced breast cancer as monotherapy or in combination with other agents.
|
|
NERLYNX 
|
NERLYNX (neratinib) is an oral pan-HER inihibitor, indicated in the European Union for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. |
|
EBVALLO▼ 
|
EBVALLO (Tabelecleucel) is an allogeneic EBV-specific T-cell immunotherapy indicated as monotherapy for treatment of adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. |
|
JAVLOR 
|
JAVLOR (vinflunine) is an antineoplasic agent indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum-containing regimen. |
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.